Korlym (mifepristone) Disease Interactions
There are 6 disease interactions with Korlym (mifepristone):
- Organ transplant
- Vaginal bleeding
- Cardiovascular disease
- Hepatic impairment
- Long QT
- Renal impairment
Mifepristone (applies to Korlym) organ transplant
Major Potential Hazard, High plausibility.
Mifepristone is contraindicated in patients with serious medical conditions, such as patients requiring treatment with systemic corticosteroids for immunosuppression after organ transplantation. Mifepristone antagonizes the effects of glucocorticoids.
Mifepristone (applies to Korlym) vaginal bleeding
Major Potential Hazard, Moderate plausibility. Applicable conditions: Endometrial Dysplasia, Abnormal Uterine Bleeding, Bleeding Associated with Coagulation Defect
Mifepristone is contraindicated in women with unexplained vaginal bleeding, and women with endometrial hyperplasia with atypia or endometrial carcinoma, as it promotes endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and vaginal bleeding. It should also be used with caution in women with hemorrhagic disorders or those receiving anticoagulation therapy.
Mifepristone (applies to Korlym) cardiovascular disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease
Mifepristone does not reduce serum cortisol levels, and elevated cortisol levels might activate mineralocorticoid receptors which are expressed in cardiac tissue. Caution should be used in patients with underlying heart conditions, including heart failure and coronary vascular disease.
Mifepristone (applies to Korlym) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
There is limited information on the safety of mifepristone in patients with mild to moderate hepatic impairment, hence the manufacturers recommend that the maximum dose should not exceed 600 mg per day. The use of mifepristone is not recommended in patients with severe hepatic disease as the pharmacokinetics in these patients have not been studied.
Mifepristone (applies to Korlym) long QT
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome
Mifepristone prolongs the QTc interval in a dose-related manner. There is little or no experience with high exposure, concomitant dosing with other QT- prolonging drugs, or potassium channel variants resulting in long QT interval. Caution and monitoring is advised if used in patients with long QT. To minimize risk, the lowest effective dose should always be used.
Mifepristone (applies to Korlym) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
No change in the initial dose of mifepristone is needed for renal impairment; but the manufacturers recommend that the maximum dose should not exceed 600 mg per day in these patients.
Korlym (mifepristone) drug interactions
There are 571 drug interactions with Korlym (mifepristone)
Korlym (mifepristone) alcohol/food interactions
There is 1 alcohol/food interaction with Korlym (mifepristone)
More about Korlym (mifepristone)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Imprints, Shape & Color Data
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- Generic Availability
- Drug class: progesterone receptor modulators
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.